Follicular Lymphoma Research Articles

Effectiveness of dose-intensified salvage regimens versus standard-dose chemotherapy for progression-free survival in early progressed follicular lymphoma before autologous stem cell transplantation: a systematic review protocol.

This review will evaluate the effectiveness of dose-intensified versus standard-dose salvage regimens on progression-free survival in early progressed follicular lymphoma before high-dose chemotherapy and autologous stem cell transplantation. Despite the substantial advances in the management of follicular lymphoma, approximately 20% of patients experience progression of the disease within 2 years of induction therapy. These patients have worse outcomes, and autologous stem cell transplantation has been shown to improve outcomes in this context. Little is known about the optimal salvage regimen. Studies must include patients ≥18 years old with early progressed follicular lymphoma who were submitted to autologous stem cell transplantation in subsequent remission. Clinical trials and observational studies will be included. The search strategy will be carried out in MEDLINE (PubMed), Embase (Periódicos CAPES), Scopus, Web of Science, LiLACS, and the Cochrane Library. No date or language restrictions will be imposed. The recommended JBI approach to critical appraisal, study selection, data extraction, and data synthesis will be used. Studies should score at least 50% in accordance with the critical appraisal tool. Data will be pooled whenever possible using the random effects model. Heterogeneity will be assessed using the standard χ 2 and I2 tests. A funnel plot will be generated to assess publication bias if there are 10 or more studies included in the meta-analysis. The GRADE approach will be used to rate certainty of evidence. PROSPERO CRD42022373345.

IBCL-541 A Comprehensive Single-Cell Multi-Omic Analysis to Depict the Biological Heterogeneity of Follicular and Large B-Cell Lymphomas

IBCL-541 A Comprehensive Single-Cell Multi-Omic Analysis to Depict the Biological Heterogeneity of Follicular and Large B-Cell Lymphomas

805MO Real-world efficacy and safety of tisagenlecleucel (CTL019) for relapse or refractory follicular lymphoma patients included in the early access program through the French DESCAR-T registry

805MO Real-world efficacy and safety of tisagenlecleucel (CTL019) for relapse or refractory follicular lymphoma patients included in the early access program through the French DESCAR-T registry

IBCL-236 Similar Safety Profile for Rituximab and Obinutuzumab as Maintenance for Follicular Lymphoma: Evidence From a Real-World Multicenter Retrospective Cohort Study

IBCL-236 Similar Safety Profile for Rituximab and Obinutuzumab as Maintenance for Follicular Lymphoma: Evidence From a Real-World Multicenter Retrospective Cohort Study

Multi-omics profiling of longitudinal samples reveals early genomic changes in follicular lymphoma

Follicular lymphoma (FL) is the most common indolent type of B-cell non-Hodgkin lymphoma. Advances in treatment have improved overall survival, but early relapse or transformation to aggressive disease is associated with inferior outcome. To identify early genetic events and track tumor clonal evolution, we performed multi-omics analysis of 94 longitudinal biopsies from 44 FL patients; 22 with transformation (tFL) and 22 with relapse without transformation (nFL). Deep whole-exome sequencing confirmed recurrent mutations in genes encoding epigenetic regulators (CREBBP, KMT2D, EZH2, EP300), with similar mutational landscape in nFL and tFL patients. Calculation of genomic distances between longitudinal samples revealed complex evolutionary patterns in both subgroups. CREBBP and KMT2D mutations were identified as genetic events that occur early in the disease course, and cases with CREBBP KAT domain mutations had low risk of transformation. Gains in chromosomes 12 and 18 (TCF4), and loss in 6q were identified as early and stable copy number alterations. Identification of such early and stable genetic events may provide opportunities for early disease detection and disease monitoring. Integrative analysis revealed that tumors with EZH2 mutations exhibited reduced gene expression of numerous histone genes, including histone linker genes. This might contribute to the epigenetic dysregulation in FL.

CREBBP histone acetyltransferase domain mutations predict response to mTOR inhibition in relapsed/refractory follicular lymphoma.

Despite the clinical and molecular heterogeneity of follicular lymphoma (FL), there remains a lack of biomarker-directed therapeutic approaches in routine clinical practice, with the notable exception of the EZH2 inhibitor tazemetostat in EZH2-mutant FL. Here we examined whether gene mutation status predicts response to clinical mTOR inhibitors (mTORi) in FL, by performing targeted mutational profiling of biopsies from 21 relapsed/refractory FL patients treated with mTORi everolimus or temsirolimus within clinical trials. We observed an enrichment of mutations within the catalytic histone acetyltransferase (HAT) domain of CREBBP in mTORi-responders, and describe distinct transcriptional characteristics and co-occurring mutations of FL harbouring these mutations; reinforcing the growing appreciation of CREBBPHAT mutation as a key biological determinant and its promise as a therapeutic biomarker in FL.

ABCL-193 Impact of Bridging Therapy (BT) on Lisocabtagene Maraleucel (liso-cel) as Second-Line (2L) or Later (2L+) Treatment of R/R Follicular Lymphoma (FL) in the Phase 2, Open-Label TRANSCEND FL Study

ABCL-193 Impact of Bridging Therapy (BT) on Lisocabtagene Maraleucel (liso-cel) as Second-Line (2L) or Later (2L+) Treatment of R/R Follicular Lymphoma (FL) in the Phase 2, Open-Label TRANSCEND FL Study

Impact of Bridging Therapy (BT) on Lisocabtagene Maraleucel (liso-cel) as Second-Line (2L) or Later (2L+) Treatment of R/R Follicular Lymphoma (FL) in the Phase 2, Open-Label TRANSCEND FL Study

Impact of Bridging Therapy (BT) on Lisocabtagene Maraleucel (liso-cel) as Second-Line (2L) or Later (2L+) Treatment of R/R Follicular Lymphoma (FL) in the Phase 2, Open-Label TRANSCEND FL Study

IBCL-278 Epcoritamab With Rituximab + Lenalidomide (R2) in Previously Untreated (1L) Follicular Lymphoma (FL) and Epcoritamab Maintenance Therapy in FL: EPCORE NHL-2 Arms 6 and 7

IBCL-278 Epcoritamab With Rituximab + Lenalidomide (R2) in Previously Untreated (1L) Follicular Lymphoma (FL) and Epcoritamab Maintenance Therapy in FL: EPCORE NHL-2 Arms 6 and 7

Epcoritamab With Rituximab + Lenalidomide (R2) in Previously Untreated (1L) Follicular Lymphoma (FL) and Epcoritamab Maintenance Therapy in FL: EPCORE NHL-2 Arms 6 and 7

Epcoritamab With Rituximab + Lenalidomide (R2) in Previously Untreated (1L) Follicular Lymphoma (FL) and Epcoritamab Maintenance Therapy in FL: EPCORE NHL-2 Arms 6 and 7

Real-World Evaluation of Treatment Pattern, Time to Next Treatment (TTNT), Health Care Resource Utilization (HCRU), and Cost of Care in Follicular Lymphoma (FL)

Real-World Evaluation of Treatment Pattern, Time to Next Treatment (TTNT), Health Care Resource Utilization (HCRU), and Cost of Care in Follicular Lymphoma (FL)

IBCL-516 Real-World Evaluation of Treatment Pattern, Time to Next Treatment (TTNT) Health Care Resource Utilization (HCRU), and Cost of Care in Follicular Lymphoma (FL)

IBCL-516 Real-World Evaluation of Treatment Pattern, Time to Next Treatment (TTNT) Health Care Resource Utilization (HCRU), and Cost of Care in Follicular Lymphoma (FL)

A Budget-Impact (BI) Analysis of Tazemetostat for the Treatment of 3L+ Relapsed or Refractory (R/R) Follicular Lymphoma (FL) in the United States

A Budget-Impact (BI) Analysis of Tazemetostat for the Treatment of 3L+ Relapsed or Refractory (R/R) Follicular Lymphoma (FL) in the United States

Follicular Lymphoma: Impact of Complete Response on Outcomes in FL: A Tertiary Care Analysis

Follicular Lymphoma: Impact of Complete Response on Outcomes in FL: A Tertiary Care Analysis

IBCL-483 First Reported Use of Polatuzumab-RCHP in Follicular Lymphoma, With Excellent Response

IBCL-483 First Reported Use of Polatuzumab-RCHP in Follicular Lymphoma, With Excellent Response

Clinical Outcomes of Patients With Relapsed/Refractory Follicular Lymphoma (R/R FL) Treated With Tisagenlecleucel: Phase 2 ELARA 3-Year Follow- Up

Clinical Outcomes of Patients With Relapsed/Refractory Follicular Lymphoma (R/R FL) Treated With Tisagenlecleucel: Phase 2 ELARA 3-Year Follow- Up

First Reported Use of Polatuzumab-RCHP in Follicular Lymphoma, With Excellent Response

First Reported Use of Polatuzumab-RCHP in Follicular Lymphoma, With Excellent Response

Nodal T Follicular Helper Cell Lymphoma Angioimmunoblastic Type Treated as a Classic Hodgkin Lymphoma: Case Report

Nodal T Follicular Helper Cell Lymphoma Angioimmunoblastic Type Treated as a Classic Hodgkin Lymphoma: Case Report

A rare thyroid cancer - case report of a follicular thyroid lymphoma

A rare thyroid cancer - case report of a follicular thyroid lymphoma

A Comprehensive Single-Cell Multi-Omic Analysis to Depict the Biological Heterogeneity of Follicular and Large B-Cell Lymphomas

A Comprehensive Single-Cell Multi-Omic Analysis to Depict the Biological Heterogeneity of Follicular and Large B-Cell Lymphomas